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Cancer is influenced by its microenvironment, yet
broader, environmental effects also play a role but
remain poorly defined.We report here thatmice living
in an enriched housing environment show reduced
tumor growth and increased remission. We found
this effect in melanoma and colon cancer models,
and that it was not caused by physical activity alone.
Serum from animals held in an enriched environment
(EE) inhibited cancer proliferation in vitro and was
markedly lower in leptin. Hypothalamic brain-derived
neurotrophic factor (BDNF) was selectively upregu-
lated by EE, and its genetic overexpression reduced
tumor burden, whereas BDNF knockdown blocked
the effect of EE. Mechanistically, we show that
hypothalamic BDNF downregulated leptin produc-
tion in adipocytes via sympathoneural b-adrenergic
signaling. These results suggest that genetic or envi-
ronmental activation of this BDNF/leptin axis may
have therapeutic significance for cancer.INTRODUCTION
The growth of most cancers is dependent in part on their micro-
environment—the balance between factors that act to facilitate
growth and induce angiogenesis and cell survival and those
that inhibit cell proliferation and lead to apoptosis (Hanahan
and Weinberg, 2000). This local microenvironment is influenced
by systemic factors, and the cancer itself induces both local and
distant changes through paracrine signaling (Aaronson, 1991)
and interactions with the immune and nervous systems (Darnell
and Posner, 2006). The effect of the macroenvironment on
systemic cancer, specifically an individual’s interaction with its
physical living and social environment is much less well defined.
There is significant interest in neuroscience in the interaction
between genes and the environment, and specifically how living52 Cell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc.in complex housing with increased space, physical activity, and
social interactions influences brain structure and function (van
Praag et al., 2000). What is remarkable is just how robust and
powerful the physical and social environment can have on brain
function. We previously published that such an enriched environ-
ment (EE) leads to changes in expression of growth factors and
survival of cells within the brain (Young et al., 1999; Cao et al.,
2004). Moreover, EE has considerable impact on the phenotype
of a variety of toxin- and genetically-induced models of human
neurological disease (Nithianantharajah and Hannan, 2006). In
cancer research, environmental effects have largely focused
on diet and exposure to mutagens and carcinogens. Here,
we wished to investigate whether the social and physical
components of an animal’s environment could impact on cancer
growth, and if so, define potential mediators. Specifically, we
were intrigued with the hypothesis, that an EE, one optimized
for cerebral health, as defined by improved learning and
memory, increased neurogenesis and reduced apoptosis and
resistance to external cerebral insults, could also lead to an anti-
cancer phenotype—in other words a mens sana associated with
a corpore sano. We therefore asked could simply placing
animals in a more complex living environment induce effects
that were profound enough to significantly influence the growth
of a highly malignant cancer? We wanted to test this in both
syngeneic models in which cancer cells continue to proliferate
following transplantation, leading to highly reproducible solid
tumors and ultimately death (Dranoff et al., 1993), as well as in
APCmin/+ mice, a spontaneous model with a germline mutation
in APC similar to humans with familial adenomatous polyposis,
and a gene in which somatic mutations occur in 80% of human
colon cancers. We show here that EE leads to a remarkable
suppression of cancer proliferation in all three models tested,
even when delayed until the tumor was well established. We
teased out the molecular pathways, and showed selective
activation of a hypothalamic-sympathoneural-adipocyte (HSA)
axis. Notably, in a comprehensive set of experiments using
transgenic animals, somatic gene transfer, controlled release,
and drug infusion, we were able to dissect out a mechanism
whereby the EE paradigm induced hypothalamic brain-derived
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Figure 1. EE Reduces Tumor Growth and Affects Biomarkers in Serum, B16 Melanoma Cell Proliferation In Vitro, Signaling Pathways in the
Tumors, and Immune Functions
(A) EE cage.
(B) Representative B16 melanoma dissected day 17 after inoculation of 105 cells per mouse. Mice were housed in the EE or control cages for 6 weeks prior to
tumor inoculation.
(C) Three weeks of EE decreased tumor volume day 19 after inoculation (n = 20 in each group, *p < 0.05).
(D) Six weeks of EE further reduced tumor weight day 17 after inoculation (n = 18 in each group, *p < 0.05).
(E) EE induced complete tumor resistance in a subset of mice. All control mice showed visible tumors.
(F) Four weeks of EE decreased tumor growth rate (n = 20 in each group, *p < 0.05).
(G) Four weeks of EE delayed the occurrence of tumor.
(H) EE effects on biomarkers in serum. Sera were collected before tumor inoculation in the 6 week EE (n = 20 in each group, *p < 0.05).
(I) B16 cells grew more slowly when cultured with serum from EE mice compared to control mice while pretreatment with leptin-neutralizing antibody inhibited the
effect of serum on B16 cell growth (n = 4 in each group, *p < 0.05 between groups as indicated).
(J) Phospho-Akt1 (S473), ERK1 (T202/Y204)/ERK2 (T185/Y187), Phospho-p38a (T180/Y182), active HIF-1a activity, and VEGF concentration were significantly
reduced in tumors from EE mice compared to control mice (n = 7 in each group, *p < 0.05).
(K) The proliferative response of splenic lymphocytes to ConA was increased in EE mice before and after tumor inoculation (n = 5 in each group at each time point,
*p < 0.05, + p = 0.054).
(L) NK cytotoxicity was higher in EE mice (n = 5 in each group, p < 0.05) before tumor inoculation.
(M) CD8 T cell cytotoxicity was higher than control mice (bar represents a pool of four mice in each group, p < 0.05).
Values are means ± standard error of the mean (SEM). See also Figure S1.neurotrophic factor (BDNF) expression as an effector immediate
early gene, leading to preferential activation of sympathetic
innervation of white adipose tissue, which in turn via b-adren-
ergic receptors led to suppression of leptin expression and
release. This marked drop in serum leptin levels mediated the
antiproliferative phenotype.RESULTS
Housing in an EE Reduces Tumor Growth
Immediately weaned (3-week-old) C57BL/6 mice were random-
ized to live in either EE (n = 18–20; Figure 1A), or in grouped
control housing (five mice per cage) for 3 or 6 weeks. Both EECell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc. 53
and control mice then received subcutaneous injections of B16
melanoma cells (105 cells per mouse) and were returned to their
respective homes. At 17 to 19 days post inoculation, tumor size
was determined (Figure 1B). In the mice housed in EE for 3 weeks
prior to tumor implantation, the mean volume of the tumor was
43% smaller than those in the control housing (p < 0.05;
Figure 1C). For the 6 week groups, the tumor mass in EE mice
was reduced by 77.2% (Figure 1D, p < 0.001). Notably, all
mice in the control groups developed solid tumors, whereas
5% of mice with 3 weeks of EE had no visible tumors, and this
tumor-resistant group reached 17% with 6 weeks EE (Figure 1E).
Moreover, the rate of tumor growth over time was both delayed
and more linear in the EE mice without the exponential growth
curve observed in the control mice (Figure 1F). The occurrence
of visible tumors were delayed in EE mice (Figure 1G) with all
control mice showing visible tumors by day 15 after inoculation
while 15% of the EE mice showed no visible tumor at day 19
when the experiment ended (Figure 1G). Reduced tumor size
in EE mice was associated with a decrease in cell proliferation
as shown by proliferating cell nuclear antigen (PCNA) immuno-
histochemistry (Figure S1A available online) as well as an
increase in apoptosis as shown by both terminal transferase
dUTP nick end labeling (TUNEL) (Figure S1B) and active caspase
3 immunoreactivity (Figure S1C).
EE Induces Systemic Metabolic Changes
We found that EE mice weighed 6% less than control mice
although being fed ad libitum on identical diets (Figure S1D).
To investigate potential systemic metabolic changes associated
with EE-induced tumor resistance, peripheral blood was taken
from the mice housed for 6 weeks in either control or EE.
Hormone and metabolite levels were measured using ELISA
kits. Insulin-like growth factor1 (IGF-1) levels have been consis-
tently associated with cancer risk and progression including
melanoma (Jenkins and Bustin, 2004). Serum IGF-1 was signifi-
cantly decreased in the EE mice (Figure 1H) while its major
binding protein, IGFBP3, did not change (data not shown). The
adipocyte hormone, adiponectin, showed a significant increase
(Figure 1H). This abundant protein is of particular interest in dia-
betes due to its role in regulating insulin sensitivity, but recently it
has been shown to have pleiotropic properties including sup-
pressing carcinogenesis and inhibiting angiogenesis in cancer
models (Fujisawa et al., 2008). As previously described for EE
(Benaroya-Milshtein et al., 2004), the adrenal glucocorticoid
and stress hormone, corticosterone was elevated (Figure 1H).
In contrast, serum leptin levels in the EE group was markedly
reduced to 13% of controls (p < 0.01; Figure 1H). Leptin is not
only the major adipocyte hormone that conveys metabolic infor-
mation to the brain but is also involved in other pathways
affecting many peripheral organs as a mitogen, metabolic regu-
lator, survival or angiogenic factor depending on the tissue type
(Wauters et al., 2000). Recent clinical reports show that elevated
serum leptin levels are linked to an increased risk of certain
cancers including prostate (Garofalo and Surmacz, 2006), breast
cancer (Cirillo et al., 2008), and melanoma (Gogas et al., 2008).
As the serum levels of factors associated with survival and
proliferation of cancer cells were influenced by EE, we investi-
gated whether B16 melanoma cells incubated with serum54 Cell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc.obtained from either EE or control mice would impact on the
cell growth in vitro using the Promega cell proliferation assay.
Sera from EE mice significantly slowed the B16 cells growth
compared to control sera (Figure 1I). Since leptin showed the
most marked change among the serum factors, we further
examined the direct role of leptin on tumor cell proliferation using
a leptin-neutralizing antibody. Pretreatment of sera with leptin-
neutralizing antibody inhibited tumor cell growth significantly
(Figure 1I).
EE Influences Signaling Pathways in the Tumor
Melanoma cells have been associated with activation of a large
number of signal transduction enzymes, which can influence
the growth of the cancer (Miller and Mihm, 2006). For example,
a genome-wide screen for oncogenes reported that 66% of
melanoma patients carry an activating mutation in the B-Raf
proto-oncogene serine/threonine-protein kinase (B-RAF), also
known as V-raf murine sarcoma viral oncogene homolog B
(BRAF) gene that leads to constitutive activation of the mitogen-
activated protein kinase (MAPK) pathway whose aberrant
activation can result in unharnessed cell proliferation (Davies
et al., 2002). These signal transduction pathways are also regu-
lated in part by extracellular mediators acting via cell surface
receptors, and since EE altered circulating levels of growth
factors, it was of interest to determine whether downstream
signal transduction pathways would be altered in the tumors
growing in EE mice. Signal transduction assays were run on
nuclear extracts using commercial kits. The tumors from EE
mice had highly significant decreases in multiple signal trans-
duction pathway mediators including phospho-Akt, phospho-
ERK1/ERK2, and phospho-p38a (Figure 1J). In addition both
active HIF-1a and vascular endothelial growth factor (VEGF)
were also decreased, consistent with a reduction in angiogen-
esis within the tumor as shown by immunostaining of vascular
marker CD31 (Figure 1J, Figure S1E).
Immunocompetence Is Enhanced in an EE
In addition to the effects on learning and memory, EE may influ-
ence immunity directly or indirectly via an interaction between
brain, neuroendocrine, and immune systems (Benaroya-Milsh-
tein et al., 2004). Spleens isolated from EE animals were signifi-
cantly enlarged compared to control animals after tumor cells
were implanted (Figure S1F). Furthermore, the splenic lympho-
cytes of EE mice showed a near 2-fold increase in proliferation
in response to the T cell mitogen Concavalin A both before
(day 0) and following tumor inoculation (days 9, 13, and 17)
(Figure 1K). In addition, natural killer cell (NK) activity was greater
in EE mice before tumor inoculation (Figure 1L), and CD8+
T cell cytotoxicity was also increased (Figure 1M), demonstrating
a significant effect on cancer cell specific immunological
responses, again consistent with cancer regression.
EE Changes Hypothalamic Gene Expression
In order to elucidate the mechanism of this EE-associated tumor
resistance, we chose to target the hypothalamus, an area of the
brain that is critical in the regulation of both energy balance and
neuroendocrine-immune interaction through the hypothalamic-
pituitary-adrenal (HPA) axis (Dhillo, 2007; McEwen, 2007). The
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Figure 2. EE Induces Gene Expression Changes in the Hypothalamus Distinctive to Voluntary Running
(A) Arcuate nucleus at 2, 4, and 9 weeks of EE.
(B) VMH/DMH (n = 5 per group).
(C) Running induced gene expression changes in the arcuate nucleus (n = 5 per group). p values of significance or strong trends are shown above the bars.
(D) Running led to some changes in serum biomarkers which were distinctive to those observed in EE (n = 16 in runners, n = 13 in control mice, *p < 0.05).
(E) The proliferative response of splenic lymphocytes to the T cell mitogen Con A was increased in runner (n = 4 in each group, *p < 0.05).
(F) NK cytotoxicity was higher in runner (n = 4 in each group, p < 0.05) before tumor inoculation.
(G) Running did not reduce tumor growth (n = 11 in runner, n = 10 in control mice, p > 0.05).
Values are means ± SEM.hypothalamus contains a number of discrete nuclei including the
arcuate (ARC), paraventricular (PVN), ventromedial (VMH), dor-
somedial (DMH), and lateral hypothalamic area (LHA). The ARC
is thought to receive information regarding metabolic status
from peripheral circulating factors including leptin, insulin,
glucose, and the gut peptides (Dhillo, 2007). The neuronal
projections from the ARC to other brain areas are thought to
mediate the effects of the ARC on energy balance. We screened
a number of genes known to be involved in metabolic regulation
and neuronal-immune crosstalk to evaluate the potential media-
tors of EE-associated metabolic and immune changes. We
housed mice in either EE or control housing for 2, 4, or 9 weeks.
The ARC was microdissected using laser capture and mRNA
expression was examined by quantitative reverse transcription
(RT)-PCR. At the early time point of 2 weeks EE, BDNF was the
only gene screened with a significant change, a 2-fold increase
(Figure 2A, left panel). It remained upregulated at 4 weeks.
Neuropeptide Y (Npy) and agouti related peptide (Agrp) expres-
sion were increased in mice with 4 weeks EE and this upregula-
tion was further increased at 9 weeks, suggesting a secondary
response to metabolic changes when exposed to long-term EE(Figure 2A, mid and right panels). Meanwhile, other genes regu-
lating food intake and energy expenditure (serum/glucocorticoid
regulated kinase, Sgk1, and nerve growth factor inducible, Vgf)
were upregulated only after 9 weeks of EE. In addition, leptin
receptor (Lepr) was significantly increased while insulin receptor
(Insr) showed a strong trend toward upregulation (Figure 2A, right
panel), indicating enhanced sensitivity of ARC neurons to periph-
eral hormonal signals. In contrast, anorexigenic peptides proo-
piomelanocortin (POMC) and cocaine-amphetamine-regulated
transcript (CART) were not changed in the ARC (data not shown).
Previous reports suggest that BDNF is most abundant in the
VMH and its secretion from the VMH and/or DMH is required
for the suppression of appetite (Rios et al., 2001; Xu et al.,
2003). We sought to examine whether BDNF expression in
VMH/DMH could also respond to EE. We microdissected
VMH/DMH using laser capture from mice living in EE for 2 weeks
and measured a number of genes known to be highly expressed
in VMH/DMH including BDNF, Junb, and Fos which have been
widely used as markers of neuronal activity. Similar to the pattern
observed in the ARC, BDNF showed a significant 2-fold upregu-
lation (Figure 2B). Interestingly, BDNF expression responds toCell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc. 55
environmental stimulation in a pattern similar to neuronal activa-
tion markers Junb and Fos (Figure 2B), and is consistent with
BDNF as a plasticity-related and effector immediate early gene
(Nedivi et al., 1993; Hughes et al., 1993).
Voluntary Wheel Running Does Not Have the Same
Effect as an EE
Physical exercise is known to enhance immune function (Suzuki
and Tagami, 2005), decrease body fat, and has recently been
shown to inhibit ultraviolet B light-induced carcinogenesis (Lu
et al., 2006). To investigate whether physical exercise could
alone account for the EE-induced melanoma resistance, we sub-
jected mice to voluntary wheel running for 4 weeks followed by
tumor implantation. Mice living in cages with free access to
running wheels ran approximately 2 km per day. Running led
to physiological changes including lower body weight, reduced
fat, and increased lean mass similar to that observed in the EE
mice (Figure S1D). Moreover, runners also showed altered
biomarkers in serum (Figure 2D), but with a pattern quite distinct
to that of EE mice (Figure 1H). In runners, IGF-1 was significantly
reduced similar to that in the EE mice. However, leptin was not
changed while both adiponectin and corticosterone were signif-
icantly decreased, in contrast to the increase in the EE mice.
Although an enhanced immune response was observed in
runners (Figures 2E and 2F), exercise did not significantly reduce
tumor weight (Figure 2G). These data suggest that physical
exercise alone is insufficient to account for EE-induced tumor
resistance although it likely contributes. Since EE consists of
a much larger environment, with access to running wheels and
various toys and objects to explore, we quantified the total phys-
ical activity of EE animals including wheel running and general
motor activity. The EE mice traveled a mean total distance of
0.64 km per day which is approximately 66% less than the
runners and further suggests physical activity per se is unlikely
the major contributor to the EE-associated tumor reduction.
Of particular interest, running influenced gene expression in
the ARC with a pattern that was qualitatively different than EE.
In contrast to the EE mice whose BDNF was increased 3-fold
at 4 weeks, running did not upregulate BDNF significantly, while
the two orexigenic peptides NPY and AgRP were increased
(Figure 2C). Hence among the genes being screened, BDNF
appeared to be the most selectively responsive to EE and could
therefore serve as a potential mediator of EE-induced tumor
resistance, while the change in expression of other genes
appeared secondary to systemic physiological changes associ-
ated with EE.
Hypothalamic Overexpression of BDNF Mimics
the Effects of an EE
BDNF has diverse functions in brain development and plasticity
(Lu et al., 2005) and its expression is highly responsive to activity
and environment (Young et al., 1999) and is considered to be an
effector immediate early gene (Hughes et al., 1993). In addition,
BDNF is an important component of the hypothalamic pathway
that controls energy homeostasis (Wisse and Scwartz, 2003).
Its expression in VMH/DMH is rapidly induced by glucose
administration consistent with a role in satiety regulation (Unger
et al., 2007). Both peripheral and central administration of BDNF56 Cell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc.decreases food intake, increases energy expenditure, and leads
to weight loss (Bariohay et al., 2005; Pelleymounter et al., 1995).
Obesity phenotypes have been observed in BDNF heterozygous
mice (Lyons et al., 1999), in a conditional knockout model
(Xu et al., 2003) and viral-mediated selective deletion in VMH/
DMH of adult mice (Unger et al., 2007). We used recombinant
Adeno-Associated Virus (rAAV) vectors to deliver an hemagglu-
tinin (HA)-tagged human BDNF gene to the hypothalamus bilat-
erally with a green fluorescent protein (GFP) vector as a control.
Four weeks after injection when transgene expression reached
stable levels (Figures 3A and 3B), mice receiving the BDNF
vector showed significantly lower body weight gain than GFP
control mice (1.25 ± 0.37 g versus 4.31 ± 0.44 g, p < 0.05). The
biomarkers in serum of BDNF mice showed the same pattern
of changes (Figure 3C) as that observed in the EE mice (Fig-
ure 1H), namely a decrease in IGF-1 and leptin, and an increase
in adiponectin and corticosterone. Leptin circulates in a free form
and is bound to soluble leptin receptor (Hahn et al., 2006). Only
free leptin is biologically active. The soluble leptin receptor level
was increased in BDNF mice (Figure 3C), leading to a further
reduction in the free leptin index. Consistent with the biomarker
changes, B16 melanoma cell growth in vitro was slower when
cultured with sera from BDNF mice compared to GFP mice
(Figure 3D). In addition, BDNF mice showed an enhanced
immune response (Figure 3E). Also similar to EE mice, tumor
weight was decreased by 75% in BDNF compared to GFP
mice (Figure 3F, p = 0.026).
BDNF Depletion Inhibits Tumor Resistance Induced
by an EE
To determine whether hypothalamic BDNF expression might be
an upstream mediator of the EE-induced metabolic profile and
anticancer phenotype, we generated a vector expressing a
microRNA targeting mouse BDNF (miR-Bdnf). In vitro experi-
ments demonstrated that this microRNA vector knocked down
BDNF mRNA by 65% and protein levels by 80%. We also gener-
ated a control microRNA vector targeting a scrambled sequence
(miR-scr) against no known genes.
We injected rAAV vectors of miR-Bdnf or miR-scr bilaterally
into the hypothalamus and then assigned the mice to EE or
control housing (Figure 4A). We measured RNAi efficiency in
the hypothalamus at both mRNA and protein levels by quantita-
tive RT-PCR and ELISA, respectively. Both BDNF mRNA
(Figure 4B) and BDNF protein levels (Figure S2) were reduced
significantly in mice receiving miR-Bdnf living in control housing
as well as EE housing compared to mice receiving miR-scr. We
assessed the specificity of miR-Bdnf by quantifying the levels of
other mRNAs and observed no significant difference in expres-
sion of housekeeping gene Actb, or the genes with sequences
most homologous to the targeting sequence of miR-Bdnf:
Bh1hb2 or Trappc6b (Figure 4B). The changes of biomarkers in
serum associated with EE was largely preserved in mice
receiving miR-scr (Figure 4D). In contrast, the EE-associated
drop in leptin levels and the increase in adiponectin was dimin-
ished in mice receiving miR-Bdnf (Figure 4D, p = 0.64 leptin level
miR-Bdnf EE versus miR-Bdnf con.; p = 0.136 adiponectin level
miR-Bdnf EE versus miR-Bdnf con.). Although not influenced by
environment, the leptin levels in miR-Bdnf mice were higher than
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Figure 3. Hypothalamic Gene Delivery of BDNF Mimics EE-Associated Metabolic Changes and Melanoma Resistance
(A) Experimental design of BDNF overexpression in the hypothalamus.
(B) Transgene expression in hypothalamus: GFP fluorescence and immunofluorescence of HA tag (human BDNF has HA tag at 30 terminal).
(C) BDNF overexpression led to serum biomarker changes similar to that found in EE (n = 10 in BDNF mice, n = 16 in GFP mice, *p < 0.05).
(D) B16 cells grew more slowly when cultured with serum from BDNF mice compared to GFP mice 4 weeks after AAV injection (n = 5 in each group, *p < 0.05).
(E) The proliferative response of splenic lymphocytes to the T cell mitogen Con A was increased in BDNF mice (n = 3 in each group, *p < 0.05).
(F) BDNF overexpression reduced tumor weight day 17 after inoculation (n = 10 in BDNF mice, n = 16 in GFP mice, *p < 0.05).
Values are means ± SEM.those in the miR-scr mice, which was consistent with the accel-
erated weight gain in miR-Bdnf mice (191.5% of miR-scr) due to
BDNF knockdown. After housing the mice in EE or control
housing for 3 weeks, we implanted B16 melanoma cells. Consis-
tent with the results we observed with naive wild-type mice, the
tumor weight was significantly reduced in miR-scr mice living in
EE compared to control housing (Figure 4C, p < 0.05 miR-scr EE
versus miR-scr con.), whereas in mice receiving miR-Bdnf this
EE effect on tumor mass was blocked (Figure 4C, p = 0.249
miR-Bdnf EE versus miR-Bdnf con.; p < 0.05 miR-Bdnf EE
versus miR-scr EE).
In order to further elucidate the role of BDNF in the tumor resis-
tance, we investigated melanoma growth in BDNF heterozygous
(BDNF+/) mice whose BDNF protein levels in the hypothalamus
is 40% lower than wild-type mice (Lyons et al., 1999). Both
BDNF+/ mice and their wild-type littermates in standard hous-
ing were injected with melanoma cells. BDNF+/ mice were
heavier (26.0 ± 0.82 g versus 23.8 ± 0.63 g) and had elevated
serum leptin levels (2902 ± 662 pg/ml versus 1178 ± 143 pg/ml,
p < 0.05) with no difference in IGF-1 levels. Tumor weight wassignificantly increased in BDNF+/ mice (896.5 ± 224.9 mg
versus 443.4 ± 102.9 mg, p < 0.05).
Sympathetic Modulation of Leptin Expression via
b-Adrenergic Receptors Mediates the Antiproliferative
Phenotype Associated with an EE
Our data showing that (1) hypothalamic overexpression of BDNF
leads to a phenotype mimicking that of EE and (2) knockdown of
BDNF expression blocks EE effects on tumor growth suggested
that hypothalamic BDNF is a mediator linking the environment to
cancer growth. We then investigated potential peripheral effec-
tors in this regulatory network. The most robust and consistent
changes among serum biomarkers associated with EE and its
impact on tumor growth were a profound decrease in leptin
and an increase in adiponectin circulating levels. Both adipo-
kines are secreted predominantly by white adipose tissue
(WAT), and serum leptin levels reflect synthesis and secretion
in WAT (Evans et al., 1999), suggesting that WAT is responsive
to EE. We examined WAT gene expression in mice living in EE.
Leptin expression was decreased approximately 50% whileCell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc. 57
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Figure 4. Hypothalamic BDNF Knockdown
Inhibits EE-Induced Tumor Resistance
(A) Experimental design of RNAi knockdown of
hypothalamic BDNF expression.
(B) Quantitative RT-PCR. The miR-Bdnf vector
significantly reduced hypothalamic BDNF mRNA
levels in mice housed in both control and EE condi-
tion (n = 7–17 per group, *p < 0.01 miR-Bdnf
compared to miR-scr in both of control housing
and EE, + p = 0.061 miR-scr EE compared to
miR-scr control housing).
(C) miR-Bdnf blocks EE-induced tumor resistance.
*p < 0.05, miR-scr EE versus all other groups. con,
control housing; EE, EE housing.
(D) Biomarkers in serum 4 weeks after AAV
injection and 3 weeks EE (*p < 0.05 miR-scr EE
versus all other groups, +p < 0.05 between groups
as indicated).
Values are means ± SEM.
See also Figure S2.adiponectin expression was increased by 70% in EE mice,
consistent with the changes observed in serum (Figure 5A).
There is considerable evidence that leptin expression is sup-
pressed by sympathetic tone via b-ARs (Evans et al., 1999; Bart-
ness and Song, 2007). All of the three b-AR genes Adrb1, 2, and 3
were upregulated by approximately 3-fold in WAT (Figure 5A)
of EE mice but not in muscle (data not shown). The EE mice
showed a trend toward higher norepinephrine (NE) levels in
serum (2.563 ± 0.187 ng/ml versus 1.811 ± 0.228 ng/ml,
p = 0.066) and a significant increase in NE level in WAT lysates
(Figure S3A), indicating elevated sympathetic drive to WAT.
Epinephrine levels were not changed in either serum (data not
shown) or WAT. Hypothalamic overexpression of BDNF also
led to an increase in WAT NE levels similar to EE (Figure S3B),
while both NE and epinephrine were significantly decreased in
WAT of BDNF+/ mice (Figure S3C), suggesting a role of BDNF
in sympathetic modulation of WAT.
We then sought to examine the potential role of the sympa-
thetic drive in mediating EE effects by using the b-blocker,58 Cell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc.propranolol. Mice receiving propranolol
(0.5 g/l) in drinking water were randomly
assigned to live in EE or control housing
for 3 weeks. The changes in serum bio-
markers associated with EE, particularly
the decrease in leptin and increase in
adiponectin levels (Figure 1H), were com-
pletely blocked when propranolol was
administered (Figure 5B). Furthermore,
EE failed to reduce tumor growth when
b-adrenergic signaling was inhibited
(p = 0.644, Figure 5C).
We further investigated the relevance of
leptin using both pharmacological and
genetic approaches. First, we implanted
mice with leptin-releasing liposomes
before exposing them to the EE. The lep-
tin-encapsulated multilamellar liposomevesicles (leptin-MLV; releasing 1.8 ng leptin/ml/24 hr in vitro)
attenuated the leptin drop associated with EE (Figure 5D) and
blocked the tumor-inhibiting effect of EE (p = 0.41 leptin-MLV
EE versus vehicle control housing; Figure 5E). Second, leptin-
deficient ob/ob mice were randomly assigned to live in control
or EE housing and a third ob/ob group receiving hypothalamic
rAAV-BDNF and placed in control housing. At 3 weeks, all
mice were implanted with melanoma cells. Tumors were larger
in ob/ob mice than wild-type mice (Figure 5F), likely due to the
general effects of obesity (Brandon et al., 2009). In contrast to
naive wild-type mice, neither EE nor hypothalamic overexpres-
sion of BDNF showed inhibition of tumor in the leptin-deficient
ob/ob mice (Figure 5F) although both groups showed lower
body weight (control housing: 39.1 ± 0.8 g, EE housing: 36.6 ±
0.9 g, rAAV-BDNF: 36.2 ± 1.2 g).
In order to rule out the possibility of obesity per se preventing
EE effects, we generated a diet-induced obesity (DIO) model
by feeding mice with a high fat diet (45% fat, caloric density
4.73 kcal/g) for 10 weeks. When the body weights of DIO
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Figure 5. Sympathetic Regulation of WAT Adipokine Expression via b-ARs Serves as a Peripheral Pathway of the EE-Associated Anticancer
Phenotype
(A) EE-induced gene expression changes in WAT of mice living in EE for 9 weeks (n = 5 per group). p values of significance were shown above bars.
(B and C) Propranolol completely blocked EE effects on serum biomarkers and melanoma growth (n = 20 per group).
(D and E) Administration of leptin-releasing liposomes attenuated the EE-associated leptin drop in circulation and inhibited the EE effect on tumor growth (n = 10
per group). *p < 0.05 compared to mice receiving vehicle and living in control housing.
(F) EE or hypothalamic overexpression of BDNF failed to inhibit melanoma growth in ob/ob mice (n = 10 per group) as observed in wild-type mice (*p < 0.05
between groups as indicated).
(G) EE inhibited tumor growth in obese DIO mice (n = 15 per group, *p < 0.05 compared to control housing).
(H) Correlation of tumor weight of individual mouse in the DIO experiment with basal serum leptin level before tumor implantation (n = 28).
(I) Leptin replacement enhanced melanoma growth in ob/ob mice compared to pair-fed saline-infused mice (n = 10 per group, *p < 0.01 compared to saline
infused mice).
Values are means ± SEM. See also Figure S3.mice were similar to those of ob/ob mice, we randomly
assigned the DIO mice to EE or control housing. Three week
EE lowered body weight and visceral fat mass including the
epididymal fat pad and retroperitoneal fat pad as well as serum
levels of leptin and IGF-1 (Figure 5G). In contrast to ob/ob
mice, EE led to a 68% reduction of tumor mass (Figure 5G,
p < 0.001). In addition, regression analysis showed a significant
positive correlation between the basal serum leptin level before
tumor implantation and subsequent tumor weight (Figure 5H,
p = 0.01).
To further define the specific role of leptin on tumor growth
from general effects associated with obesity, we carried
out a leptin replacement experiment in ob/ob mice using
osmotic minipumps to deliver leptin (0.3 mg/kg/d for 14 days).
The leptin replacement supplied physiological levels of leptin(1.97 ± 0.31 ng/ml) and decreased food intake by approximately
50% compared to ob/ob mice receiving saline. We pair fed a
third group of mice receiving saline to the leptin replacement
group. All of the mice were injected with melanoma cells 4 hr
after minipump implantation. The leptin-infused mice showed
similar body weight and fat mass as the pair-fed saline-infused
mice (Figure 5I). However, the tumor weight was 140% greater
in leptin-infused mice than pair-fed saline mice (Figure 5I), further
supporting leptin’s role in melanoma growth.
Importantly, these experiments showed a consistent inverse
relationship between circulating leptin and tumor mass, inde-
pendent of body weight. Moreover, data in ob/ob mice as well
as wild-type mice living in control or EE housing showed no
correlation between body weight change and subsequent tumor
mass following transplantation.Cell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc. 59
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Figure 6. EE Inhibits Colon Cancer GrowthWhenCommenced after MC38 Implantation and Suppresses Intestinal Tumorigenesis in ApcMin/+
Mice
(A) Experimental design of the minimal disease model.
(B) In the minimal disease MC 38 model, EE significantly reduced tumor weight (n = 20 per group, *p < 0.05).
(C) EE affects biomarkers in the minimal disease model (n = 20 per group, *p < 0.05).
(D) Experimental design of the established MC38 model.
(E) In the established tumor model, EE commenced after visible tumor occurred reduced tumor growth rate (n = 6 per group, *p < 0.05).
(F) EE decreased tumor weight day 24 after tumor inoculation (n = 6 per group, *p < 0.05).
(G) Serum biomarkers in ApcMin/+ mice after 3 weeks EE (n = 15 per group, *p < 0.05).
(H) Total number of visible tumors larger than 1 mm in diameter (n = 15 EE, n = 14 control, p = 0.01).
(I) EE reduced the size of polyps in small intestine (*p < 0.05).
(J) EE reduced splenomegaly (n = 15 EE, n = 14 control, p < 0.01).
(K) EE reduced triglyceride level (n = 15 EE, n = 14 control, p < 0.01).
Values are means ± SEM.EE Housing Improves Survival in a Colon Cancer Model
after the Tumor Is Established
To determine whether our results could be generalized, we
studied another well-defined murine cancer model, the MC38
colon cancer. Moreover, we also investigated whether this inter-
vention could influence tumor growth after the cancer had been
established. We used two cancer models: first, a minimal
disease model in which EE was initiated 4 days after tumor inoc-
ulation before the presence of any visible tumors, and second, an
established tumor model in which EE was initiated following the
development of visible tumors. In the minimal disease model,
naive mice received subcutaneous implantation of MC38 colon
cancer cells (105 cells per mouse) and were housed in identical
standard conditions for 4 days. Half of the mice were then
randomly assigned to live in the EE with the other half remaining
in control housing. When large tumors were observed in control60 Cell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc.mice 17 days later, the experiment was terminated (Figure 6A).
Tumor weight was significantly reduced in EE mice by 40% ±
11% compared to control mice (Figure 6B), with 10% of EE
mice bearing a barely palpable tumor of 25 mg or less. The serum
biomarkers in EE mice when carrying the colon cancer showed
changes similar to those observed in EE mice before tumor inoc-
ulation (Figure 1H), namely an increase in adiponectin and
a reduction in leptin (Figure 6C). Consistent with the B16 mela-
noma experiment, MC38 colon cancer cells also grew more
slowly in vitro when cultured with sera from EE mice compared
to control mice (data not shown). In the established tumor model,
mice received 3 3 104 tumor cells and were maintained in iden-
tical housing for 6 days until visible tumors were observed and
then randomized to either EE or control housing (Figure 6D).
The growth rate of the established tumor was markedly reduced
even in this paradigm in which EE was delayed. Tumor size was
reduced by 44% at 12 days and 55% at 18 days (Figure 6E) with
tumor weight decreased by a comparable degree (Figure 6F).
Suppression of Intestinal Tumorigenesis in ApcMin/+
Mice in an EE
To determine whether the EE-induced tumor suppression in
tumor implant models could be effective in spontaneous tumor-
igenesis models more relevant to human disease, we chose to
use the ApcMin/+ model of intestinal cancer. The ApcMin/+ mouse
contains a germline mutation in the adenomatous polyposis coli
(APC) tumor suppressor gene leading to mice highly susceptible
to spontaneous intestinal adenoma formation (Su et al., 1992).
Mutation of APC is common to most human colon cancers being
found in 80% of all colorectal adenomas and carcinomas and is
also one of the earliest mutations in colon cancer progression
(Goss and Groden, 2000). Therefore the ApcMin/+ mouse has
been extensively used as an animal model in understanding
colon cancer biology and progression as well as in the evaluation
of potential therapeutic interventions. We randomly assigned
male ApcMin/+ mice 7 weeks of age to live in EE or control
housing. After 3 weeks of EE housing, we measured biomarkers
in serum and found similar EE-associated changes (Figure 6G)
as those observed in wild-type mice (Figure 1H), namely a sharp
drop in leptin and increases in adiponectin and corticosterone
levels. One of the mice in control housing died at 11 weeks of
age while all EE mice survived to the end of the experiment at
13 weeks of age. We blindly examined the entire intestine and
scored all visible polyps larger than 1 mm. EE significantly
reduced the total number of polyps within the small intestine
by 46% (Figure 6H, p = 0.01). EE also substantially reduced
the size of polyps with a 50% reduction in all polyps greater
than 3 mm in diameter, and no polyps larger than 4 mm
(Figure 6I). Splenomegaly occurs in ApcMin/+ mice and spleen
size is directly related to the polyp burden (Mehl et al., 2005).
Consistent with the reduction in polyp burden, EE significantly
reduced splenomegaly by 40% (Figure 6J). Hyperlipidemia is
also associated with adenoma formation in ApcMin/+ mouse (Su
et al., 1992) with EE decreasing triglyceride level by 61%
(Figure 6K).
DISCUSSION
Our results demonstrate that EE significantly reduces cancer
burden in both a syngeneic melanoma as well as a colon cancer
model. Moreover, the intervention was further generalizable to
a spontaneous cancer model, the Apcmin/+ mouse, whose muta-
tion is a common and early event of human colon cancer
progression. Moreover, a significant subset of EE mice remained
tumor free while all the controls had tumors. In addition, EE
was effective even though it was initiated after the establish-
ment of the peripheral tumor, suggesting potential therapeutic
relevance.
The relative tumor resistance in the EE mice was associated
with changes in the endocrine axis as well as enhanced immune
responses. EE consists of more complex housing with sensory,
cognitive, motor, and social stimulation (Nithianantharajah and
Hannan, 2006). This complexity is further manifest in the interac-
tion between the central nervous, endocrine, and immunesystems. The pathways involved serve as components of a larger
regulatory network that impact on a host’s response to cancer. It
is unlikely that a single variable accounts for all the effects of EE
although it is plausible that changes in the brain play a central
role with the peripheral pathways as secondary effectors. The
enriched living condition with increased dynamic social interac-
tions, frequent exposure to novel objects, and enhanced phys-
ical activity leads to a small (within the physiological range),
but statistically significant increase in serum corticosterone. In
contrast, runners had a decrease in resting corticosterone.
This corticosterone elevation in EE mice is consistent with
a mild stress and activation of the HPA. It seems paradoxical
that chronic, mild activation of the HPA axis could be associated
with a tumor-resistant phenotype. However, classical stress
literature would consider the EE ‘‘eustress’’ (positive stress) as
opposed to maladaptive ‘‘distress’’ (negative stress), which is
associated with exposure to more severe aversive or hostile
environments (Selye, 1974; Milsum, 1985). More recently, the
concept of allostasis has been used to describe adaptive
responses to external challenges (Sterling and Eyer, 1988).
Hence, aversive stress may lead to allostatic overload resulting
in a compromised axis, poorly equipped to respond to external
stressors, and many maladaptive changes including organ
dysfunction and suppression of the immune system (McEwen,
1998). In contrast, the allostasis associated with exposure to
the mild, nonaversive challenges of EE leads to a more adaptive
HPA axis and may therefore buffer the reaction to subsequent
major external stressors (Benaroya-Milshtein et al., 2004;
Larsson et al., 2002).
The central components of the stress system within the central
nervous system (CNS) include corticotrophin-releasing hormone
(CRH) and the noradrenergic/sympathetic neurons of the hypo-
thalamus and brainstem, which regulate the peripheral activity
of the HPA axis and the sympathetic nervous system (SNS).
These two arms act in a coordinated manner, resulting in adap-
tations in an animal’s physiological and behavioral state inte-
grated at many levels including the hypothalamus (McDougall
et al., 2005), a brain structure critical to the crosstalk between
the CNS, endocrine, and immune systems. Here we observed
that the EE paradigm activated the hypothalamus with induction
of the immediate early genes, Fos, Junb, and BDNF. This data is
consistent with reports showing that acute immobilization stress
induces a rapid increase in BDNF mRNA expression in the hypo-
thalamus preceding the activation of CRH neurons, suggesting
that hypothalamic BDNF is involved early in the regulation of
the HPA axis (Rage et al., 2002; Naert et al., 2006).
In our study, genetic overexpression of BDNF in the hypothal-
amus increased CRH expression (Cao et al., 2009) and HPA
activity, which is consistent with other studies using central
administration of BDNF protein (Naert et al., 2006). Our results
suggest that the EE effect on sympathetic tone is likely one of
the mechanisms underlying the tumor resistance, with hypotha-
lamic BDNF a critical mediator and WAT as the principal periph-
eral organ responsive to this central regulation (Figure 7). WAT
receives sympathetic innervation from cell groups that are part
of the general SNS outflow from the brain including hypothalamic
PVN, VMH, and ARC (Bartness and Song, 2007). Our data
suggest hypothalamic BDNF expression signals to increaseCell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc. 61
Figure 7. Mechanism of EE-Induced Tumor Resistance
See Discussion for details.SNS outflow to WAT. In turn, the sympathetic nerves innervating
WAT release NE which activates b-ARs and subsequently leads
to lipid mobilization, higher energy expenditure, and changes in
adipokine production—in particular, an increase in adiponectin
and a decrease in leptin and their respective circulating concen-
trations. Notably, the b-AR blocker propranolol fully inhibited
the EE-associated changes in leptin and adiponectin and
completely abolished the inhibition of tumor growth, suggest-
ing a link between b-AR activity in WAT, circulating leptin/
adiponectin levels, and tumor growth. The relationship of leptin/
adiponectin with oncogenesis and cancer proliferation is not fully
elucidated. However, accumulating clinical and experimental
evidence supports a role of these adipokines in the development
and progression of several cancers including melanoma and
colon cancer (Gogas et al., 2008; Barb et al., 2007) via either
a direct influence on cellular proliferation and/or indirect effects
on inflammation and angiogenesis (Fujisawa et al., 2008; Bran-
don et al., 2009). We also observed that leptin significantly
enhanced both B16 melanoma and MC38 colon cancer cell
growth in culture while in contrast, adiponectin significantly
inhibited tumor cell growth in vitro (data not shown). The rele-
vance of leptin in EE-induced tumor inhibition was further inves-
tigated using both pharmacological and genetic approaches.
First, when exogenous leptin was delivered via controlled-
release liposomes to offset the EE-induced decrease in endoge-
nous leptin levels, the EE-induced tumor reduction was inhibited.62 Cell 142, 52–64, July 9, 2010 ª2010 Elsevier Inc.Second, both EE and hypothalamic overexpression of BDNF
failed to reduce tumor growth in leptin-deficient ob/ob mice
despite a reduction in body weight. In contrast, the equally obese
DIO mice responded to EE with a marked reduction in tumor
growth indicating obesity per se does not prevent the effect of
EE on tumor growth. Our data showed that obesity increases
melanoma growth in both genetically obese ob/ob and diet-
induced obese mice. This data is consistent with a recent report
that shows B16 melanoma growth is accelerated in both obese
ob/ob mice as well as obese MC4R knockout mice. However,
prevention of obesity by pair feeding ob/ob mice dramatically
reduces tumor weight to a level significantly lower than in wild-
type mice of the same weight (Brandon et al., 2009). Our leptin
replacement data also showed that leptin increased melanoma
mass in ob/ob mice by 140% compared to pair-fed saline-
infused mice with identical body weight and fat mass. Moreover,
although leptin levels are typically used as a surrogate marker of
fat mass and body weight, our data showed that whereas base-
line leptin levels consistently and strongly correlated with tumor
mass, no such relationship existed for body weight per se, both
in the setting of ob/obmice and nonobese wild-type mice. Taken
together, leptin is likely a critical peripheral effector linking EE
with tumor inhibition.
It is known that physical activity enhances natural immunity
and the number and activity of NK cells in the circulation fluc-
tuate greatly during and after exercise and in response to other
stressors (Jonsdottir, 2000). NK cells are mainly driven from
the spleen into the circulation depending on sympathetic outflow
and ambient catecholamine levels. Hence, the observed NK
activity change may also be a result of altered NK distribution.
The enhanced NK activity in enriched mice can be partly
explained by increased sympathetic activity similar to that
shown for ‘‘mirthful laughter’’ (Nagatomi, 2006). Given the role
of NK cells in tumor immunity, modulation of the immune system
is likely a contributor to the tumor resistance phenotype we
observed. However, voluntary running did not lead to significant
decrease of tumor weight, although its effect on immune function
was comparable to that of EE, suggesting only a partial role
of immune modulation in the observed tumor suppression.
Therefore, our data is consistent with a model in which WAT adi-
pokines, driven by hypothalamic BDNF-induced sympathetic
outflow, serve as the major downstream effectors of the complex
regulatory network leading to an antiproliferative phenotype.
In summary, our results demonstrate that living in an EE leads
to significant inhibition of cancer growth. Here we propose one
mechanism, the activation of the HSA axis. Specifically, the
induction of hypothalamic BDNF expression in response to
environmental stimuli leads to sympathoneural activation. The
elevated sympathetic drive activates adipocyte b-ARs inhibiting
leptin expression and release, and increasing adiponectin
expression and circulating concentrations. These adipokines
have both direct mitogenic (leptin) and antimitogenic (adiponec-
tin) activity, and in addition can influence peripheral tumor
growth indirectly including effects on angiogenesis. At a clinical
level, our data shows that direct gene transfer of BDNF can
mimic the antiproliferative effects of EE, and suggests that either
environmental or direct molecular approaches to induce hypo-
thalamic BDNF expression may have therapeutic potential.
EXPERIMENTAL PROCEDURES
Environmental Enrichment Protocol
Male 3-week-old C57/BL6 mice were housed in groups (18–20 mice per cage)
in EE cage as detailed in the Extended Experimental Procedures. We carried
out all mice experiments in compliance with the regulations of the Institutional
Animal Ethics Committees.
Microdissection with Laser Capture
We randomized mice 3 weeks of age to live in standard housing or EE for 2, 4,
and 9 weeks. At each time point, brains were isolated and stored at80C until
microdissection as detailed in the Extended Experimental Procedures.
AAV-Mediated BDNF Overexpression
We generated AAV serotype 2 vectors of human BDNF as detailed in the
Extended Experimental Procedures. We randomly assigned 26 C57BL/6
mice, male, 8 weeks of age, to receive AAV-BDNF (n = 10) or AAV-GFP (n =
16). rAAV vectors (13 1010 genomic particles per site) were injected bilaterally
into the hypothalamus at the stereotaxic coordinates 1.2 AP, ±0.5 ML, 6.2
DV (mm from bregma) using a microinfusion pump. Four weeks after AAV
injection, we withdrew blood and inoculated B16 melanoma cells.
ob/obMice EE and Hypothalamic BDNF Overexpression Experiment
We randomly assigned 30 male ob/ob mice (Jackson Laboratory), 4 weeks of
age, to live in EE, control housing, or receive AAV-BDNF as described above
and living in control housing, n = 10 per group. We inoculated melanoma cells
3 weeks after EE or AAV injection.
ApcMin/+ Mice Experiment
Male C57BL/6J-ApcMin/+ mice were purchased from the Jackson Laboratory.
Seven-week-old male ApcMin/+ mice were randomly assigned to live in the EE
or standard housing for 6 weeks (n = 15 per group). The location, number, and
size of visible tumors in the entire intestine were determined under a dissection
scope.
Statistical Analysis
Values are expressed as mean ± standard error of the mean (SEM). We used
one-way ANOVA to analyze tumor volume, tumor weight, ELISA, and tumor
cell proliferation in culture. We used multivariate ANOVA to analyze quantita-
tive RT-PCR data. For the immune cell proliferation and cytotoxicity, we deter-
mined the overall significance using repeated-measures ANOVA.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
three figures and can be found with this article online at doi:10.1016/j.cell.
2010.05.029.
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